• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胆汁性肝硬化清醒大鼠对血管紧张素II的内脏血管收缩反应减弱。

Reduced splanchnic vasoconstriction to angiotensin II in conscious rats with biliary cirrhosis.

作者信息

Braillon A, Cailmail S, Gaudin C, Lebrec D

机构信息

Unité de Recherches de Physiopathologie Hépatique (INSERM U-24), Hôpital Beaujon, Clichy, France.

出版信息

J Hepatol. 1993 Jan;17(1):86-90. doi: 10.1016/s0168-8278(05)80526-4.

DOI:10.1016/s0168-8278(05)80526-4
PMID:8445224
Abstract

Decreased pressor reactivity to angiotensin II has been demonstrated in portal hypertension due to cirrhosis. The present study investigated the respective roles of portal hypertension and cirrhosis and the hemodynamic mechanisms of the depressor response in different models of portal hypertension in conscious rats. Dose-pressor curves were studied in sham-operated, portal vein stenosed (portal hypertension without cirrhosis) and biliary cirrhotic rats following angiotensin II administration. Decreased pressor response was observed in cirrhotic rats but not in portal vein stenosed rats. The hemodynamic effects of angiotensin II administration (11 ng.100 g-1 body wt.min-1, i.v.) were studied in conscious sham-operated and biliary cirrhotic rats (radioactive microsphere method). The percentage of change from basal values following angiotensin II administration were significantly more marked in sham-operated rats than in cirrhotic rats for mean arterial pressure (+34 vs. +6%), cardiac index (-36 vs. -22%), systemic vascular resistance (+117 vs. +40%). After angiotensin II, portal tributary and hepatic artery blood flows significantly decreased in sham-operated rats (-31 and -14%, respectively) but not in cirrhotic rats (+1 and +23%), whereas changes in renal blood flow were not significantly different between the two groups (-44 vs. -34%). In conclusion, in biliary cirrhotic rats, decreased pressor response to angiotensin II depends on the presence of liver disease rather than on portal hypertension or basal hemodynamic alterations. It also depends on the decreased vasoconstrictive effect which predominates in the splanchnic vascular bed.

摘要

肝硬化所致门静脉高压患者对血管紧张素II的升压反应降低。本研究在清醒大鼠不同门静脉高压模型中,探讨门静脉高压和肝硬化各自的作用以及降压反应的血流动力学机制。在假手术、门静脉狭窄(无肝硬化的门静脉高压)和胆汁性肝硬化大鼠中,给予血管紧张素II后研究剂量-升压曲线。肝硬化大鼠出现降压反应降低,而门静脉狭窄大鼠未出现。在清醒假手术和胆汁性肝硬化大鼠中(放射性微球法),研究了静脉注射血管紧张素II(11 ng·100 g-1体重·min-1)的血流动力学效应。血管紧张素II给药后,与肝硬化大鼠相比,假手术大鼠的平均动脉压(+34%对+6%)、心脏指数(-36%对-22%)、全身血管阻力(+117%对+40%)相对于基础值的变化百分比明显更显著。给予血管紧张素II后,假手术大鼠的门静脉分支和肝动脉血流显著减少(分别为-31%和-14%),而肝硬化大鼠未减少(+1%和+23%),而两组间肾血流变化无显著差异(-44%对-34%)。总之,在胆汁性肝硬化大鼠中,对血管紧张素II的降压反应降低取决于肝脏疾病的存在,而非门静脉高压或基础血流动力学改变。它还取决于内脏血管床中占主导的血管收缩作用降低。

相似文献

1
Reduced splanchnic vasoconstriction to angiotensin II in conscious rats with biliary cirrhosis.胆汁性肝硬化清醒大鼠对血管紧张素II的内脏血管收缩反应减弱。
J Hepatol. 1993 Jan;17(1):86-90. doi: 10.1016/s0168-8278(05)80526-4.
2
Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension.前列环素在伴有肝外或肝内门静脉高压的清醒大鼠血流动力学改变中的作用。
Hepatology. 1993 Sep;18(3):621-7.
3
Dose-dependent effects of a nitric oxide biosynthesis inhibitor on hyperdynamic circulation in two models of portal hypertension in conscious rats.一氧化氮生物合成抑制剂对清醒大鼠两种门静脉高压模型中高动力循环的剂量依赖性作用。
J Gastroenterol Hepatol. 1996 Jan;11(1):1-6. doi: 10.1111/j.1440-1746.1996.tb00002.x.
4
Effects of terlipressin on hemodynamics and oxygen content in conscious portal vein stenosed and cirrhotic rats receiving propranolol.特利加压素对接受普萘洛尔治疗的清醒门静脉狭窄性肝硬化大鼠血流动力学和氧含量的影响
J Hepatol. 1993 Jan;17(1):102-7. doi: 10.1016/s0168-8278(05)80529-x.
5
Acute haemodynamic effects of losartan in anaesthetized cirrhotic rats.氯沙坦对麻醉肝硬化大鼠的急性血流动力学影响。
Eur J Clin Invest. 2003 Nov;33(11):1006-12. doi: 10.1046/j.1365-2362.2003.01251.x.
6
Vascular, hemodynamic and renal effects of low-dose losartan in rats with secondary biliary cirrhosis.低剂量氯沙坦对继发性胆汁性肝硬化大鼠的血管、血流动力学及肾脏影响
Liver Int. 2005 Jun;25(3):657-66. doi: 10.1111/j.1478-3231.2005.01053.x.
7
Adenosine and hemodynamic alterations in cirrhotic rats.肝硬化大鼠的腺苷与血流动力学改变
Am J Physiol. 1991 Apr;260(4 Pt 1):G543-7. doi: 10.1152/ajpgi.1991.260.4.G543.
8
Capsaicin treatment blocks development of hyperkinetic circulation in portal hypertensive and cirrhotic rats.辣椒素治疗可阻断门静脉高压和肝硬化大鼠高动力循环的发展。
Am J Physiol. 1993 May;264(5 Pt 1):G868-73. doi: 10.1152/ajpgi.1993.264.5.G868.
9
Effects of glucagon on systemic and splanchnic circulation in conscious rats with biliary cirrhosis.
J Hepatol. 1989 Jul;9(1):69-74. doi: 10.1016/0168-8278(89)90077-9.
10
Hemodynamic effects of dopamine in conscious rats with secondary biliary cirrhosis.多巴胺对继发性胆汁性肝硬化清醒大鼠的血流动力学影响。
J Hepatol. 1990 Sep;11(2):257-62. doi: 10.1016/0168-8278(90)90122-8.

引用本文的文献

1
Acute-on-chronic liver disease enhances phenylephrine-induced endothelial nitric oxide release in rat mesenteric resistance arteries through enhanced PKA, PI3K/AKT and cGMP signalling pathways.急慢性肝病通过增强蛋白激酶 A、磷脂酰肌醇 3-激酶/蛋白激酶 B 和环鸟苷酸信号通路增强苯肾上腺素诱导的大鼠肠系膜阻力动脉内皮型一氧化氮释放。
Sci Rep. 2019 May 6;9(1):6993. doi: 10.1038/s41598-019-43513-y.
2
Hemodynamic effects of one week of carvedilol administration on cirrhotic rats.卡维地洛给药一周对肝硬化大鼠的血流动力学影响。
J Gastroenterol. 2006 Apr;41(4):361-8. doi: 10.1007/s00535-006-1782-5.
3
Vascular contractile response and signal transduction in endothelium-denuded aorta from cirrhotic rats.
肝硬化大鼠去内皮主动脉的血管收缩反应及信号转导
World J Gastroenterol. 2005 Apr 21;11(15):2306-12. doi: 10.3748/wjg.v11.i15.2306.
4
The relationship between intrahepatic portal systemic shunts and microsphere induced portal hypertension in the rat liver.大鼠肝脏内肝门静脉分流与微球诱导的门静脉高压之间的关系。
Gut. 1998 Feb;42(2):276-82. doi: 10.1136/gut.42.2.276.
5
Vasoconstrictor responsiveness of the rat mesenteric arterial bed in cirrhosis.肝硬化大鼠肠系膜动脉床的血管收缩反应性
Br J Pharmacol. 1996 May;118(2):435-41. doi: 10.1111/j.1476-5381.1996.tb15421.x.